Epstein-Barr virus-induced, posttransplant lymphoproliferative disorders

Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV- PTLD) continues to be a major complication after solid organ transplantatio n in high-risk patients. Despite the identification of risk factors that pr edispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD ham per the optimal management of this transplant complication. This review sum marizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for futu re areas of study.